Kornimate/medical-research-clean huggingface dataset:
palliative thoracic immunort

Conditions: Lung Cancer, Nonsmall Cell; Lung Cancer

Summary: the trial is designed as a prospective observational single arm study investigating stage iv non-small cell lung cancer patients who are routinely treated with a pd-1 inhibitor for indications approved by health canada. all patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 gy in 10 fractions.


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed ajcc 7th/8th edition stage iv adenocarcinoma or squamous cell carcinoma not eligible for curative treatment. 2. indication and suitability to receive palliative radiotherapy to the thorax (30gy/10). 3. receiving or planned to receive nivolumab or pembrolizumab 4. prior history of systemic chemotherapy is permitted given a washout period of 4 weeks 5. age 18 or older 6. ecog performance status 0-2 7. life expectancy greater than 3 months 8. able and willing to provide informed consent 9. able to complete patient reported outcome questionnaires exclusion criteria: 1. contraindications to radiotherapy, including a history of sle, systemic scleroderma, ipf, ataxia telangiectasia 2. previous history of thoracic radiotherapy with an overlapping field 3. previous history of checkpoint inhibitor related pneumonitis or esophagitis 4. pregnancy
monitoring chronic urticaria basophil irritability by cytometry

Conditions: Urticaria

Summary: a biological tool for quantitative assessment of chronic urticaria (cu) is still in need for monitoring biotherapies. cu is considered as a sudden degranulation of mast cells / basophils without any identified cause. it is considered that mast cell/basophil have an abnormally high sensitivity in cu and can be triggered with almost nothing (high irritability). in allergy, basophils degranulation can be reproduced in vitro with allergens. anti-ige (immunoglobulin e) antibody mimics allergen triggering of basophils in a dose dependent manner. if basophils are abnormally sensitive in cu, it should be reproduced in vitro at very low stimulation. the main objective of this project is to set up a method to evidence abnormal basophil irritability and look for clinical significance. as many markers characterize basophils in different states, researchers shall also look for a profile possibly associated with cu basophile irritability. such tests could be useful in cu monitoring.

mast cell is a key factor in urticaria physiopathology. several mechanisms have been hypothesized and could be either synergistic or revealing different types of urticaria. but most of these mechanisms seem to converge to mast cells releasing histamine and other products. these mechanisms include auto-antibody and / or cytokines inappropriate production. however, internal dysregulation of mast cell have also been reported, that could be either primary or secondary to extrinsic mediators mentioned already. basophils closely related to mast cells, easily accessible and usually serve as surrogate for clinical analysis of allergy or urticaria. flow-cytometry (fcm) is a recent tool with increasing interest due to its exceptional capacity of analysis of a large number of cells, individually, at high speed and measuring many parameters at a time. fcm has been extensively used in characterization of cell sub populations in several diseases such as hematology disorders or immunology and among them the basophil. fcm is now the gold standard for ex vivo functional analyses of basophil activation as part of the diagnosis of allergy. the present project aims to explore phenotypic and functional changes that could reflect the dysregulation in urticaria. this would have diagnosis and physiopathological interest with potential impact on optimizing disease monitoring and treatment.

Eligibility criteria:
inclusion criteria: * patients : * active chronic urticaria according to the eaaci 2014 criteria. * healthy volunteers : * age (approx. +/- 5 years matched with patient group), * sexe matched. exclusion criteria: * patients * treated by omalizumab * healthy volunteers : * allergy, * atopy, * urticaria.
phase iv, open-label, multicenter study of dasatinib in chronic-phase chronic myeloid leukemia (cp-cml) patients with chronic, low-grade non-hematologic toxicity to imatinib

Conditions: Chronic Phase Chronic Myeloid Leukemia

Summary: this study proposes to evaluate the number of chronic, grade 1 or 2, non-hematologic adverse events (aes) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.


Eligibility criteria:
inclusion criteria: * patients with cml-cp patients achieving an optimal response to imatinib treatment with grade 1 or 2 non-hematologic adverse events persisting for at least 2 months or recurring at least 3 times in the preceding 12 months, despite best supportive care * men and women with chronic myeloid leukemia- chronic phase (cml-cp) ph+ ≥ age 18 * daily eastern co-operative group (ecog) performance status = 0 - 2 * patient willing and able to give informed consent * life expectancy \> 6 months * adequate renal function * adequate hepatic function exclusion criteria: * patients who are pregnant or breast feeding * men whose partner is unwilling to avoid pregnancy. * previous treatment with any other tyrosine-kinase inhibitor (tki), except for imatinib * current grade 3 or 4 imatinib related adverse event * prior documented t315i mutation * prior diagnosis of accelerated phase or blast crisis cml * previous loss of complete hematologic response (chr) or major cytogenetic response (mcyr) on imatinib * concurrent medical condition of uncontrolled infection, cardiovascular diseases of cardiac failure, congenital long qt syndrome, ventricular arrhythmias, prolonged qt interval, second or third degree heart block, uncontrolled angina, myocardial infarction (mi) in the last 6 months, uncontrolled hypertension, pulmonary arterial hypertension, pleural or pericardial effusions, or history of bleeding disorder
take-care program: effectiveness of a physical therapy program on cancer related symptoms

Conditions: Breast Cancer

Summary: effectiveness of a physical therapy program focussed on core stability exercise and massage as a recovery method in breast cancer survivors after oncology treatment.

eligibility criteria 1, had a diagnosis of breast cancer (stage i-iiia); 2, between 25-65 years; 3, finished co-adjuvant treatment except hormone-therapy; 4, not having active cancer; 5, interest to improve their lifestyle increasing physical activity; and, 6, present 3 to 5 of the following physical findings, judged by the oncologist who referred the patient: neck or shoulder pain symptoms, reduced range of motion in neck- shoulder area, reduced physical capacity, any psychological problem, increased fatigue, sleep disturbances, or any problem in coping with reduced physical and psychosocial functioning. principal outcomes fatigue score: piper fatigue scale mood state:profile of mood state quality of life: qlq-br23

Eligibility criteria:
inclusion criteria: * finished oncology treatment (chemotherapy, radiation, surgery) exclusion criteria: * other musculoskeletal conditions.

Keywords: breast cancer physical therapy massage core stability
application of hyperspectral imaging analysis technology in the diagnosis of colorectal cancer based on colonoscopic biopsy

Conditions: Colorectal Neoplasms; Colorectal Polyp; Colorectal Adenoma; Colorectal SSA

Summary: the purpose of this study is to develop and validate a deep learning algorithm for the diagnosis of colorectal cancer other colorectal disease by marking and analyzing the characteristics of hyperspectral images based on the pathological results of colonoscopic biopsy, so as to improve the objectiveness and intelligence of early colorectal cancer diagnosis.

prospectively collect the hyperspectral image information of ordinary colonoscopic biopsy tissue. the colonoscopic biopsy tissue is from the endoscopy center of qilu hospital of shandong university. the hyperspectral images are marked based on the biopsy pathological results, and the deep convolutional neural network (dcnn) model is used. with training and verification, develop the hyperspectral imaging artificial intelligence diagnostic system (hsiaids) .a portion of colonoscopic biopsy tissue will be collected as a prospective test set to prospectively test the diagnostic performance of the hsiaids algorithm.

Eligibility criteria:
inclusion criteria: * patients aged 18-75 years who undergo the colonoscopy examination and biopsy exclusion criteria: * patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in colonoscopy * patients with previous surgical procedures on the gastrointestinal tract. * patients with contraindications to biopsy * patients who refuse to sign the informed consent form

Keywords: hyperspectral imaging artifitial intelligence colorectal cancer
follow-up study of mesenchymal stem cells for bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: this is a follow-up study to investigate the long-term safety and efficacy of human umbilical cord -derived mesenchymal stem cells (huc-mscs), for the treatment of bpd in premature infants. subjects who participated in and completed the initial stage of the phaseⅰtrial (nct03558334 ) will be followed-up until 48 months after the huc-mscs transplantation.

subjects who completed the initial stage of the phaseⅰclinical trial will be followed-up at 5 additional visits: 1, 3, 6, 12 and 24 months after the huc-mscs transplantation.

Eligibility criteria:
inclusion criteria: 1. subject who completed the safety and efficacy evaluations in huc-mscs phaseⅰ clinical trial 2. subject with a written consent form signed by a legal representative or a parent exclusion criteria: 1. subject whose parent or legal representative does not agree to participate in the study 2. subject who is considered inappropriate to participate the study by the investigator

Keywords: bronchopulmonary dysplasia human umbilical cord -derived mesenchymal stem cells
a study investigating the clinical parameters associated with the use of ryzodeg® (insulin degludec/insulin aspart) in a real-world adult population with type 2 diabetes in south korea

Conditions: Diabetes Mellitus, Type 2

Summary: this is a non-interventional (observational), retrospective medical record review study collecting data reported in medical records of patients with t2d (type 2 diabetes ) who were treated with any basal-insulin or premix-insulin (plus/minus oad (oral antidiabetic drug)) for at least 26 weeks prior to switching to ryzodeg® and treated for at least 26 weeks after switching to ryzodeg® (plus/minus oad). all patients have been treated at the discretion of the treating physician in accordance with the ryzodeg® label in south korea.


Eligibility criteria:
inclusion criteria: * male or female, age above or equal to 19 years at the time of ryzodeg® initiation * type 2 diabetes mellitus patients * treated with any basal-insulin (plus/minus oad (oral antidiabetic drug)) or premix-insulin (plus/minus oad) for at least 26 weeks prior to switching to ryzodeg® * treated with ryzodeg® (plus/minus oad) for at least 26 weeks after switch from any basal insulin (plus/minus oad) or premix insulin (plus/minus oad) * at least more than once documented medical visit for 26weeks (plus/minus 6 weeks) after ryzodeg® initiation * minimum available data : age, type of diabetes at the time of ryzodeg® initiation, hba1c \[three values: most recent value within 26 weeks (plus/minus 6 weeks) prior to ryzodeg® initiation, a value of ryzodeg® initiation date (plus/minus 6 week), and a value in the first 26 weeks (plus/minus 6 weeks) after ryzodeg® initiation\] * the decision to treat with ryzodeg® was taken by treating physician independently from decision to include patient in study. exclusion criteria: * patients treated with any diabetic investigational drug within 26 weeks before or after the initiation of ryzodeg® * patients switching to ryzodeg® below 26 weeks prior to the data collection date * patients not treated with any basal-insulin or premix-insulin at least 26 weeks prior to receiving ryzodeg® * patients treated by continuous subcutaneous insulin infusion prior to receiving ryzodeg® * pregnancy patient * patients not treated with the local licensed ryzodeg®
aerobic exercise versus digital cognitive behavioral therapy for insomnia

Conditions: Insomnia Chronic

Summary: the purpose of this study is to compare the effects of aerobic exercise versus digital cbt-i in university students with insomnia complaints. this is a clinical trial. participants will be randomized into two groups: aerobic exercise (n=25) and digital cbt-i (n=25). the severity of insomnia, sleep quality, pre-sleep cognitive and somatic arousal, and participants' complaints of depression, anxiety, and stress will be assessed using self-administered questionnaires. based on previous studies describing the effects of physical exercise on chronic insomnia, the hypothesis of this study is that aerobic exercise promotes similar results compared to digital cbt-i in insomnia severity and sleep quality, in addition to improving the complaints of depression, anxiety and stress of the participants.


Eligibility criteria:
inclusion criteria: * ages ≥ 18 years old * insomnia severity index score \>8 * be physically inactive according to the ipaq questionnaire exclusion criteria: * non-adherence to intervention protocols * absence or incomplete answers in the questionnaires/evaluation methods of the study * shift workers

Keywords: chronic insomnia exercise sleep anxiety depression
oral hycamtin plus whole brain radiation therapy in treatment of brain metastases resulting from non-small lung cancer

Conditions: Lung Cancer, Non-Small Cell

Summary: the current prognosis for patients with metastatic brain cancer from nsclc is very poor. the current standard treatment for this disease is radiation therapy to the brain. the goal of the current study is to test whether the combination of orally administered hycamtin capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition.


Eligibility criteria:
inclusion criteria: * at least one measurable cancerous lesion in the brain from primary non-small cell lung cancer (nsclc) * must have received previous chemotherapy * must be 18 years of age of greater * must be easter cooperative oncology group (ecog) performance status 0, 1, 2 * at least 2 weeks must have elapsed since any surgery * at least 4 weeks must have elapsed since any radiation to a non-cns site * must have adequate bone marrow, renal, and live capacities * women must be of non-childbearing potential or practice adequate birth control * males must practice adequate methods of birth control * must sign written informed consent exclusion criteria: * previous whole brain radiation therapy * prior treatment with topotecan * investigational agent within 30 days or 5 half-live * concomitant therapy with inhibitors of breast cancer resistance protein (bcrp) or p-glycoprotein such as erlotinib or gefitinib * primary or secondary immunodeficiencies * gastrointestinal conditions that affect gi absorption or motility * uncontrolled emesis * brain metastasis at time of initial diagnosis of nsclc * history of other malignancy except in situ carcinoma of cervix; nonmelanomatous skin cancer, low grade prostate cancer * pregnant or intending to become pregnant or intending to father a baby * any severe concurrent medical condition that could affect compliance.

Keywords: brain metastases from non-small cell lung cancer brain metastases brain tumor lung cancer oral chemotherapy hycamtin topotecan nsclc wbrt whole brain radiation
quilt-2.015: a study of amg 479 with exemestane or fulvestrant in postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer

Conditions: Breast Cancer; Breast Tumors; Metastatic Cancer

Summary: this is a randomized, double-blind, placebo-controlled, phase 2 study. subjects will include postmenopausal women with confirmed hr-positive, locally advanced or metastatic breast cancer, who have disease progression during or within 12 months after completing prior adjuvant endocrine therapy or during the first prior endocrine therapy for metastatic disease.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed carcinoma of the breast with locally advanced or metastatic disease * confirmation of hormone receptor (hr) positive disease status * amenable to receive endocrine therapy * disease progression while receiving prior endocrine therapy for locally advanced or metastatic breast cancer * postmenopausal woman ≥ 18 years old exclusion criteria: * hr-unknown or hr-negative disease * not amenable to endocrine therapy * central nervous system metastasis

Keywords: postmenopausal hormone receptor positive locally advanced metastatic
effect of daily vinegar ingestion for four weeks on mood state in healthy college students

Conditions: Mood; Depression

Summary: the objective of this research is to record mood states and depression levels in healthy college students before and after 4 weeks of daily vinegar ingestion.

recent research suggests that fruit and vegetable intake is inversely associated with mood states and depression. although the mechanism is not known, increased gut fermentation is suspected as changes in gut tryptophan metabolism was noted in these trials. tryptophan is the precursor to serotonin, the neurotransmitter associated with improved mood state, but other metabolites of tryptophan have been associated with mental wellbeing as well. the main ingredient of vinegar, acetic acid, is the most common metabolite produced during gut fermentation of dietary fiber (mainly from fruits and vegetables) and can also be expected to influence the gut microbiome. it has been reported that vinegar ingestion is linked to a change in tryptophan metabolism in healthy adults consuming vinegar daily for 8 weeks. this study will explore the impact of vinegar ingestion on mood states.

Eligibility criteria:
inclusion criteria: * college student, non-athlete, no chronic health condition exclusion criteria: * vegetarians or others adhering to special diet, body mass index \>30 kg/m2, pregnancy/lactation, unwilling to ingest vinegar

Keywords: acetic acid
ifn-dli for relapsed acute leukemia after allo-sct

Conditions: Leukemia

Summary: this trial is designed to determine the feasibility of conventional induction chemotherapy, ifnand g-csf mobilized dli (ifn-dli) in subjects with relapsed aml and all after allo-sct.


Eligibility criteria:
inclusion criteria: dli recipient * relapsed aml or all ≥ 60 days after allogeneic sct. * evidence of residual donor chimerism on most recent analysis (within 4 weeks of enrollment). * age ≥ 18 years of age, * karnofsky performance status ≥ 60%. * absence of active gvhd and off immunosuppression. subjects on tapering prednisone will be eligible if their dose is 0.25 mg/kg or less and being actively tapered. we suggest a 28 day waiting period off of immunosuppression but some subjects with rapidly progressive disease may need to be treated before 30 days and will still be eligible. * adequate organ function: cr ≤ 2 mg/dl; alt/ast \< 3x uln, direct bili \<3x uln. * matched sibling or un-related donor (a, b, c, and dr) available to undergo leukopheresis. * subjects must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing. * willing to provide blood samples for research purposes. * willing to adhere to medically accepted form of birth control to prevent pregnancy (includes: complete abstention from intercourse, condoms, diaphragms, cervical cap, intra-uterine device, history of surgical sterility - tubal ligation or vasectomy in patient or partner, or oral contraceptive). dli donor 1. hla identical to recipient subject. 2. considered medically eligible for leukopheresis procedure by independent donor physician (university of pennsylvania physician who is not the recipient's primary transplant physician for related donors; physician designated by national marrow donor program for unrelated donors). 3. considered medically eligible to receive g-csf (filgrastim) by independent donor physician. exclusion criteria recipient * prior cell therapy for relapse within the past 90 days. * requirement for active immunosuppression to treat gvhd. * pregnant or lactating women. the safety of this therapy on unborn children and effects on breast milk are not known. * uncontrolled active infection * any uncontrolled active medical disorder that would preclude participation as outlined. donor - unable to participate in a leukopheresis procedure or receive g-csf (filgrastim).
evaluation of a cincalcet suppression test

Conditions: Parathyroid Hormone Suppression Test With Cinacalcet

Summary: the aim of the study is to compare the results of a parathyroid hormone (pth)suppression test using a single oral tablet of cinacalcet in two groups of subjects: 1- a group of healthy adults in whom the results of the test with cinacalcet will be compared with those of the standardized pth suppression test with intravenous calcium loading; 2- a group of patients with proven primary hyperparathyroidism in whom the results of the test with cinacalcet will be compared with those obtained during the same test, in healthy controls.


Eligibility criteria:
inclusion criteria: * control group: healthy adult (\>18 years), having signed informed consent, taking no treatment, with effective contraception in unmenopausal women, with normal clinical examination, with normal plasma pth, calcium, phosphorus, 25 oh vitamin d levels, with normal renal function, with normal 24 hour calciuria. * primary hyperparathyroidism group: adult patients (\>18 years), having signed informed consent, with effective contraception in unmenopausal women, taking no treatment known to modify calcium-phosphorus status, with normal bmi, in which the diagnosis of primary hyperparathyroidism was confirmed on plasma pth, calcium, phosphorus, 25 oh vitamin d levels, with normal renal function, with 24 hour calciuria higher than normal. exclusion criteria: * control group: significant medical or surgical history, creatinine clearance \<60 ml/min, liver insufficiency, arterial hypertension, psychiatric disorder able to modify the compliance to the study, tobacco intoxication, taking a treatment known to modify calcium-phosphorus status, severe known allergy, pregnant women, unmenopaused women without contraception. * primary hyperparathyroidism group:secondary hyperparathyroidism, creatinine clearance \<60 ml/min, liver insufficiency, psychiatric disorder able to modify the compliance to the study, tobacco intoxication, taking a treatment known to modify calcium-phosphorus status, severe known allergy, pregnant women.

Keywords: parathyroid hormone cinacalcet primary hyperparathyroidism diagnosis